Palvella submits first NDA module for QTORIN rapamycin

1 min read Updated on 29 Jun 2026, 05:59 PM

Reviewed by

Anirudha BScanX News Team

AI Summary

Palvella Therapeutics has initiated the FDA rolling review process for QTORIN 3.9% rapamycin anhydrous gel, a potential first-in-class therapy for microcystic lymphatic malformations, by submitting the first module of its NDA. The company aims to complete the submission in the second half of 2026, with a potential U.S. launch in the first half of 2027, supported by Breakthrough Therapy, Orphan Drug, and Fast Track designations.

*this image is generated using AI for illustrative purposes only.

Palvella Therapeutics, Inc. has submitted the first module of its rolling New Drug Application (NDA) to the FDA seeking approval of QTORIN 3.9% rapamycin anhydrous gel for the treatment of microcystic lymphatic malformations (microcystic LMs). The submission initiates the FDA's rolling review process, facilitating an expedited review that allows the agency to evaluate completed sections before the full application is finalized. Palvella remains on track to complete the NDA submission in the second half of 2026 and is accelerating U.S. launch readiness for a potential standalone commercial launch in the first half of 2027, if approved.

QTORIN rapamycin has the potential to become the first FDA-approved therapy and standard of care for the estimated more than 30,000 individuals in the U.S. with microcystic LMs, a rare, chronically debilitating genetic disease driven by dysregulation of the PI3K/mTOR pathway. The therapy is designed to deliver rapamycin directly to pathogenic skin tissue to achieve local, on-target inhibition of mTOR signaling while minimizing systemic exposure. The Phase 3 SELVA study demonstrated highly statistically significant improvements across the primary endpoint, key secondary endpoint, and all prespecified secondary endpoints.

"Initiating the rolling NDA submission represents an important milestone in advancing QTORIN rapamycin toward potential approval for patients living with microcystic LMs," said Jeff Martini, Ph.D., Chief Scientific Officer of Palvella Therapeutics. "We are completing the remaining NDA modules and U.S. launch-readiness activities with urgency, discipline, and a deep sense of responsibility to the patients, families, and physicians we seek to serve," added Wes Kaupinen, Founder and Chief Executive Officer.

The company has recruited core leadership across its commercial, medical affairs, and patient services organizations to prepare for the launch. In March 2026, Palvella launched the BEYOND mLM campaign and BeyondMLM.com in collaboration with patient advocacy groups to increase disease awareness and support earlier diagnosis.